Letov

Letov

letrozole

Manufacturer:

Zydus Cadila

Distributor:

Pharmaland

Marketer:

Pharmaland
Concise Prescribing Info
Contents
Letrozole
Indications/Uses
Adjuvant treatment of postmenopausal women w/ hormone receptor positive early breast cancer. Extended adjuvant treatment of early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy. 1st-line treatment in postmenopausal women w/ hormone-dependent advanced breast cancer. Treatment of advanced breast cancer in women w/ natural or artificially-induced postmenopausal status, who have previously been treated w/ antioestrogens.
Dosage/Direction for Use
Adult 2.5 mg once daily. In adjuvant & extended adjuvant setting, treatment should continue for 5 yr or until tumor relapse occurs. In metastatic disease, continue until tumor progression is evident.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Premenopausal endocrine status. Pregnancy & lactation.
Special Precautions
For postmenopausal women only. Close supervision for renal (CrCl <10 mL/min) & hepatic (Child-Pugh C) impairment. May increase total serum cholesterol & decrease in bone mineral density. May impair ability to drive or operate machinery. 
Adverse Reactions
Headache, dizziness, insomnia, somnolence, nausea, vomiting, constipation, diarrhea, cough, nasal congestion, hot flushes, hypercholesterolemia, edema, chest pain, HTN.
Drug Interactions
May increase the levels/effects of CYP2A6 substrates eg, dexmedetomidine & ifosfamide. Decreased levels/effects w/ tamoxifen.
ATC Classification
L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Presentation/Packing
Form
Letov FC tab 2.5 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in